Naoko Takebe to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications Naoko Takebe has written about Clinical Trials, Phase I as Topic.
Connection Strength
2.306
-
Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
Score: 0.642
-
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer. 2017 May; 20(3):481-488.
Score: 0.529
-
Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6.
Score: 0.498
-
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
Score: 0.201
-
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
Score: 0.145
-
Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
Score: 0.135
-
Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Semin Radiat Oncol. 2016 10; 26(4):271-80.
Score: 0.131
-
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
Score: 0.026